MLR assay quote request

Compound screening by Mo-DC: T cell reactivity

new revvity page message
From planning and execution to data analysis, we have the expertise to move your project forward.
One of the team will be in touch within 48 hours

Horizon’s Standard MLR assay services

Send us your biologics or small molecules, and our proven method will analyze its effects on multiple endpoints from multiple allogeneic donors. We designed optimised 3-fold dose response of 8 points testing up to 16 compounds from a single set of primary cells.

  • Short project completion – from 4 weeks
  • Donor-donor reproducibility
  • Robust data pack

 

Standard MLR assay read-outs

The data you will get include:

  • Interferon-gamma (IFN-γ) cytokine release
  • T cell viability
  • T cell proliferation by flow cytometry of:
    • % CTV of CD4+
    • % CTV of CD8+
    • % CD25

 

Our cloud-based data report include

  • Cell quality control metrics
  • Assay performance QC
  • Response curves plots
  • Raw Data and Metadata

 

Mixed Lymphocyte Reaction assay workflow

 

Service description Number of suitable compounds Catalog Number
Standard MLR assay - Mini  1 to 4 IMM01-01
Standard MLR assay - Midi  5 to 10 IMM01-02
Standard MLR assay - Maxi  11 to 16 IMM01-03

Request pricing for the three sizes available and a sales representative will be in touch within 48 hours.

Contact us to discuss your next project


Required fields marked with * Required

Immunology services

Answer questions in biologically relevant primary immune cell types
  • Leverage our expertise screening in immune cell types
  • Receive robust data from high-throughput assays

View MLR assay data

Access the MLR assay appnote. See how the Mixed Lymphocyte Assay assay can help advance your research.

Validate your target hits

With Horizon's expert cell-based screening services Need a trusted partner to support your validation studies? Our expert team of screening scientists can help you achieve actionable results quickly. View the brochure to learn more.